EN EN
EUROPEAN
COMMISSION
Brussels, XXX
CA-July13-Doc.3.1
[…](2013) XXX draft
COMMISSION IMPLEMENTING REGULATION (EU) No …/..
of XXX
to approve IPBC as an existing active substance for use in biocidal products for product -
type 6
(Text with EEA relev ance)EN 2 ENCOMMISSION IMPLEMENTING REGULATION (EU) No …/..
of XXX
to approve IPBC as an existing active substance for use in biocidal products for product -
type 6
(Text with EEA relevance)
THE EUROPEAN COMMI SSION,
Having regard to the Treaty on the Functioning of t he European Union ,
Having regard to Regulation (EU) No 528/2012 of the European Parliament and of the 
Counc il of 22 May 2012 concerning the making available on the market and use of biocidal 
products1, and in particular the third subparagraph of Article 89(1)thereof ,
Whereas:
(1) Commission Regulation (EC) No 1451/2007 of 4 December 2007 on the second phase 
of the 10 -year work programme referred to in Article 16(2) of Directive 98/8/EC of 
the European Parliament and of the Council concerning the placing of bio cidal 
products on the market2establishes a list of active substances to be assessed, with a 
view to their possible inclusion in Annex I, IA or IB to Directive 98/8/EC. That list 
includes IPBC.
(2) Pursuant to Regulation (EC) No 1451/2007, IPBChas been evalua ted in accordance 
with Article 11(2) of Directive 98/8/EC for use in product -type 6, in-can preservatives , 
as defin ed in Annex V to that Directive, which corresponds to product -type 6as 
defined in Annex V to Regulation (EU) No 528/2012.
(3) Denmark was design ated as Rapporteur Member State and submitted the competent 
authority report, together with a recommendation, to the Commission on 27 June 2011
in accordance with Article 14(4) and (6) of Regulation (EC) No 1451/2007.
(4) The competent authority report was rev iewed by the Member States and the 
Commission. I n accordance with Article 15(4) of Regulation (EC) No 1451/2007, the 
findings of the review were incorporated, within the Standing Committee on Biocidal 
Products on 27 September 2013 ,in an assessment report.
(5) It appears from the evaluations that biocidal products used for product -type 6and 
containing IPBCmaybe expected to satisfy the requirements laid down in Article 5 of 
Directive 98/8/EC . Italso appears from the report that such biocidal products maybe 
expected to satisfy the requirements laid down in Article 19 of Regulation (EU) No 
528/2012, provided that the conditions specified in the Annex to this Regulation are 
satisfied.
(6) It is therefore appropriate to approve IPBC for use in biocidal products for product -
type 6.
  
1OJ L 167, 27. 6.2012, p. 1.
2OJ L 325, 11.12.2007, p. 3.EN 3 EN(7) Since the evaluation did not a ddress nanomaterials, the approval should not cover such 
materials pursuant to Article 4(4) of Regulation (EU) No 528/2012.
(8) A reasonable period should be allowed to elapse before an active substance is 
approved , in order to permit Member States , interested parties , and the Commission 
where appropriate, to prepare themselves to meet the new requirements entailed .
(9) The measures provided for in this Regulation are in accordance with the opinion of the 
Standing Comm ittee on Biocidal Products ,
HAS ADOPTED THIS REGULATION:
Article 1
IPBCshall be approved as an active substance for use in biocidal products for product -type 6, 
subject to the specifications and conditions set out in the Annex to this Regulation .
Article 2
This Regulation shall enter into force on the twentieth dayfollowing that of its publication in 
the Official Journal of the European Union .
This Regulation shall be binding in its entirety and directly applicable in all Member States.
Done at Brussels, 
For the Commission
The President
José Manuel BARROSOEN 4 ENANNEX 
Common 
Nam eIUPAC Name
Identification NumbersMinimum 
degree of 
purity of 
the active 
substance3Date of 
approvalExpiry date 
of approvalProduct 
typeSpecific condit ions4
IPBC IUPAC Name : 
3-iodo-2-propynyl butylcarbamate
EC n° : 259-627-5
CAS n° : 55406 -53-6980 g/kg 1 July 
2015 30 June
20256The product assessment shall pay particular 
attention to the exposures, the risks and the 
efficacy linked to any uses covered by an 
application fo r authorisation, but not 
addressed in the Union level risk 
assessment of the active substance .
Authorisations are subject to the following 
condition :
For industrial or professional users, safe 
operational procedures and appropriate 
organizational measures shall be 
established. Only where exposure cannot 
be reduced to an acceptable level by other 
means, products shall be used w ith 
appropriate personal protective equipment.
  
3The purity indicated i n this column was the minimum degree of purity of the active substance used for the evaluation made in accordance with Articl e 8 of Regulation (EU) No 
528/2012 . The active substance in the product placed on the market can be of equal or different purity if it has been proven technically equivalent with the evaluated active 
substance
4For the implementation of the common principles of Annex VI of Regulation (EU) No 528/2012 , the content and conclusions of assessment reports are available on the 
Commission w ebsite: http://ec.europa.eu/comm/environment/biocides/index.htm